Navigation Links
VCU Massey Cancer Center study shows enzyme linked to spread of breast cancer cells

Researchers at the Virginia Commonwealth University Massey Cancer Center have found a new signaling component that influences movement of human breast cancer cells toward epidermal growth factor.

In the August issue of the Journal of Biological Chemistry, researchers showed that epidermal growth factor, which plays a critical role in breast cancer progression, stimulates sphingosine kinases - SphK1 and SphK2 - a family of enzymes that forms the potent lipid mediator, sphingosine-1-phosphate, and that breast cancer cells are unable to move without these kinases.

"If we understood how tumor cells spread or metastasize, we would be able to design better tools to help treat cancers," said lead author Sarah Spiegel, Ph.D., chair and professor in the VCU Department of Biochemistry and co-leader of the Massey Cancer Center Cell Signaling program.

Spiegel, who is internationally recognized for her pioneering work on new lipid mediators that regulate cell growth and cell death, and her colleagues, first discovered the role of sphingosine-1-phosphate in cell growth regulation nearly a decade ago. While researchers know that SphK1 is stimulated by multiple growth factors, less is known about how SphK2 is regulated. Spiegel and her team are continuing this work to better understand the functions of these enzymes.

"Our work suggests that sphingosine kinases are potential new targets in cancer therapy," she said.


'"/>

Source:Virginia Commonwealth University


Page: 1

Related biology news :

1. Massey Cancer Center researcher helps to identify a piece of the cancer puzzle
2. VCU Massey Cancer Center researchers identify a new class of anti-cancer drugs based on platinum
3. Massey researchers induce cell death in leukemia
4. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
5. Jump-starting T Cells In Skin Cancer
6. Deficient DNA Repair Capacity Associated With Increased Risk Of Breast Cancer
7. Fox Chase Cancer Center scientists identify immune-system mutation
8. Breakthrough Microarray-based Technology for the Study of Cancer
9. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
10. Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery
11. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017  Socionext Inc., a ... prototype of a media edge server, the M820, which features the ... face recognition software provided by Tera Probe, Inc., will be showcased ... and at the NAB show at the Las Vegas ... ...
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
Breaking Biology Technology: